What Are GLP-1 Agonists? The Drug Class Behind Modern Weight Loss and Type 2 Diabetes Care

Key Takeaways

• GLP-1 agonists are synthetic peptides that mimic glucagon-like peptide-1, a gut hormone released after eating. They bind the GLP-1 receptor on pancreatic, stomach, and brain cells.
• The class includes semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Adlyxin). Tirzepatide (Mounjaro, Zepbound) is a related dual GIP/GLP-1 agonist.
• Mean weight loss in published trials ranges from about 6% on liraglutide 3.0 mg (Pi-Sunyer et al., NEJM 2015) to 14.9% on semaglutide 2.4 mg (Wilding et al., NEJM 2021) over 68 weeks.
• The most common side effects are nausea, diarrhea, constipation, and vomiting, mostly during dose escalation. Serious risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma in animal models.

Direct answer (40-60 words)

GLP-1 agonists are a class of injectable and oral peptide drugs that activate the glucagon-like peptide-1 receptor. They lower blood glucose by triggering insulin release, suppress glucagon, slow gastric emptying, and reduce appetite through brain receptors in the hypothalamus. Approved members include semaglutide, liraglutide, dulaglutide, and exenatide.

Table of contents

1. The 30-second answer
2. What GLP-1 is and why mimicking it works
3. The full list of approved GLP-1 agonists
4. Mechanism of action: four pathways at once
5. Clinical efficacy: weight, A1C, and cardiovascular outcomes
6. Side effects and contraindications
7. How GLP-1 agonists differ from each other
8. Compounded semaglutide and how it fits in
9. Who is a candidate and how the drugs are prescribed
10. FAQ
11. Sources

What GLP-1 is and why mimicking it works

GLP-1, glucagon-like peptide-1, is a 30-amino-acid hormone secreted by L-cells in the lower small intestine within minutes of food entering the gut. It's an incretin, a hormone that amplifies the insulin response to a meal. Native GLP-1 has a half-life of about two minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) chops it apart almost as fast as the gut releases it.

That short half-life is why people with type 2 diabetes can't simply be given GLP-1 itself. The drug class works by modifying the peptide so DPP-4 can't cleave it. Liraglutide adds a fatty acid chain that binds albumin and shields the peptide. Semaglutide adds a longer fatty acid plus two amino acid substitutions, extending the half-life to about 165 hours. Dulaglutide fuses GLP-1 to an antibody fragment. Each modification trades injection frequency for cost and complexity.

The result is a molecule that triggers the same receptor as native GLP-1, but stays in circulation long enough to act on the pancreas, gut, and brain for hours or days at a time.

The full list of approved GLP-1 agonists

As of 2026, the FDA-approved GLP-1 receptor agonists in the United States are:

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is sometimes lumped in with this class, but it activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism produces larger weight loss in head-to-head trials (Frias et al., NEJM 2021).

Albiglutide (Tanzeum) was approved in 2014 and withdrawn in 2018 for commercial reasons.

Mechanism of action: four pathways at once

GLP-1 agonists work through several tissue-specific actions that together drive weight loss and glycemic control.

Pancreas. Activation of the GLP-1 receptor on beta cells causes glucose-dependent insulin release. The "glucose-dependent" part matters: insulin is only secreted when blood glucose is elevated, which is why hypoglycemia is rare on GLP-1 monotherapy. The same receptor on alpha cells suppresses glucagon, which further lowers hepatic glucose output (Drucker, Cell Metab 2018).

Stomach. GLP-1 slows gastric emptying. In tirzepatide trials, gastric emptying half-time roughly doubles versus placebo (Davies et al., Diabetes Care 2023). Slower emptying flattens the post-meal glucose spike and prolongs satiety. It's also the mechanism behind the most common side effects, nausea and reflux.

Brain. GLP-1 receptors in the hypothalamus and brainstem reduce appetite and food reward. Functional MRI studies show reduced activation in reward centers when patients on semaglutide view high-calorie food images (Hanssen et al., Diabetes Obes Metab 2023). This central action is why patients describe the medication as quieting "food noise."

Cardiovascular. Long-term outcome trials show reductions in major adverse cardiovascular events. SUSTAIN-6 (Marso et al., NEJM 2016) found a 26% relative risk reduction in cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke for semaglutide versus placebo in patients with type 2 diabetes.

Clinical efficacy: weight, A1C, and cardiovascular outcomes

The published trials read consistently across the class, though magnitude varies.

The two practical takeaways: (1) higher doses move weight more, with diminishing returns above semaglutide 2.4 mg. (2) Tirzepatide's dual mechanism produces larger losses than any single GLP-1 agonist in published head-to-head data, though it's technically not a pure GLP-1 drug.

For context, the FDA's threshold for an obesity drug to be approved is an additional 5% weight loss versus placebo. Every drug above clears that bar by a wide margin.

Side effects and contraindications

Across the class, the most common adverse events involve the gastrointestinal tract.

• Nausea (15 to 45% during titration)
• Diarrhea (10 to 20%)
• Constipation (10 to 15%)
• Vomiting (5 to 15%)
• Acid reflux (5 to 10%)
• Decreased appetite (often desired)

Less common but serious:

• Pancreatitis (rare, FDA labels list it)
• Gallbladder disease, especially during rapid weight loss
• Acute kidney injury, often related to dehydration from vomiting
• Diabetic retinopathy progression in patients with rapid A1C drops

The FDA boxed warning for semaglutide and liraglutide notes that rodent studies showed thyroid C-cell tumors. The clinical relevance in humans is unclear. The drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.

The safety profile is well-characterized after more than 15 years of clinical use (exenatide was first approved in 2005). Long-term data through five years on semaglutide and dulaglutide show stable safety signals.

How GLP-1 agonists differ from each other

Within the class, the practical differences are pharmacokinetic and tolerability-based.

Half-life. Twice-daily exenatide has a 2.4-hour half-life. Semaglutide and dulaglutide last around 5 days, allowing weekly dosing. The longer half-lives mean smoother blood levels and fewer spikes in nausea.

Receptor selectivity. All "GLP-1 agonists" hit only the GLP-1 receptor. Tirzepatide adds GIP receptor activation, which appears to enhance weight loss and may slightly reduce nausea per dose-response trials.

Weight-loss potency. Semaglutide and tirzepatide produce the largest losses in published trials. Older agents (exenatide, liraglutide for diabetes) are less potent for weight specifically.

Cost and access. Brand-name semaglutide and tirzepatide cost roughly $1,000 to $1,400 per month at U.S. retail. Insurance coverage for obesity is inconsistent. Compounded versions of semaglutide are sometimes available at lower cost when an FDA shortage status allows compounding.

A 2026 deep-dive on choosing between the molecules is available in our semaglutide vs tirzepatide guide.

Compounded semaglutide and how it fits in

Compounded semaglutide is sterile semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved. Compounded products are legal in two situations: when the brand-name drug is on the FDA Drug Shortage list (503A pharmacy compounding under section 503A of the FD&C Act), or for documented patient-specific clinical needs.

Compounded semaglutide became widely available during the 2022-2024 brand-name shortage. As of 2026, the regulatory status has shifted. Patients considering compounded options should review the prescribing pharmacy's licensing, third-party potency testing, and the source of the active pharmaceutical ingredient.

For the full picture, see our compounded semaglutide explainer.

Who is a candidate and how the drugs are prescribed

The FDA-approved indications for GLP-1 agonists in obesity require a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbid condition (hypertension, type 2 diabetes, dyslipidemia, sleep apnea). For type 2 diabetes, the indications are broader and don't require a BMI threshold.

Prescribing typically happens through a primary care provider, endocrinologist, obesity medicine specialist, or telehealth platform with licensed providers. The standard sequence is:

1. Medical evaluation including weight history, comorbid conditions, contraindications, and medication review.
2. Baseline labs (typically A1C, lipid panel, basic metabolic panel; sometimes thyroid function and lipase).
3. Starting dose selection (low dose to minimize nausea).
4. Titration over 4 to 16 weeks to a maintenance dose.
5. Follow-up at 4 to 12 week intervals to adjust dose, manage side effects, and monitor outcomes.

Most clinical guidelines recommend continuing the medication for at least 12 months before assessing efficacy. Patients who lose less than 5% of body weight after 6 months on a maintenance dose are often switched or discontinued.

FAQ

What does GLP-1 agonist mean? A GLP-1 agonist is a drug that binds and activates the glucagon-like peptide-1 receptor, mimicking the natural gut hormone GLP-1. This produces insulin release after meals, slows gastric emptying, and reduces appetite. Examples include semaglutide, liraglutide, and dulaglutide.

Are GLP-1 agonists the same as Ozempic? Ozempic is one specific GLP-1 agonist (the brand name for weekly injectable semaglutide). The class includes other drugs as well, including Wegovy (also semaglutide, dosed for obesity), Trulicity (dulaglutide), Saxenda and Victoza (liraglutide), Byetta and Bydureon (exenatide), and Rybelsus (oral semaglutide).

Is tirzepatide a GLP-1 agonist? Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. It's classified as a dual agonist or "twincretin." Trials show larger weight loss than pure GLP-1 agonists, and the side effect profile is similar with slightly less per-dose nausea.

How quickly do GLP-1 agonists work? Appetite suppression often begins within the first week. Glycemic effects are measurable within 2 to 4 weeks. Most weight loss accumulates over 6 to 18 months as patients titrate to higher doses and adapt to the medication. Trial mean weight change is typically reported at 56 to 72 weeks.

Do GLP-1 agonists work for people without diabetes? Yes. Semaglutide 2.4 mg (Wegovy), liraglutide 3.0 mg (Saxenda), and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults without diabetes who meet BMI criteria. Trial weight-loss outcomes are similar in patients with and without type 2 diabetes, though slightly larger in non-diabetic populations.

What happens if you stop a GLP-1 agonist? Most patients regain weight after discontinuation. The STEP 4 extension trial (Rubino et al., JAMA 2021) found patients who stopped semaglutide regained two-thirds of lost weight within a year. The drugs treat obesity as a chronic condition; outcomes are tied to ongoing therapy.

Can you take GLP-1 agonists long-term? Available long-term data extends to about 5 years on semaglutide and dulaglutide. Safety has remained stable across that interval. Most obesity medicine guidelines support indefinite use as long as the medication is tolerated and continues to provide benefit.

Are GLP-1 agonists safe in pregnancy? No. All currently approved GLP-1 agonists are contraindicated in pregnancy. Patients planning pregnancy should discontinue at least 2 months before conception (for semaglutide, given its long half-life). Animal studies show fetal harm at clinical exposure levels.

Do GLP-1 agonists cause hypoglycemia? Rarely, when used as monotherapy. Insulin release is glucose-dependent, so the drugs don't drive blood sugar below normal. Hypoglycemia risk increases when GLP-1 agonists are combined with sulfonylureas or insulin, in which case those medications are typically dose-reduced.

Why do GLP-1 agonists cause nausea? Slowed gastric emptying keeps food in the stomach longer than the brain expects. The vagal nerve signals nausea in response to gastric distension. Central GLP-1 receptors in the area postrema (a brain region involved in vomiting) also contribute. Nausea typically peaks 24 to 72 hours after a dose change and improves over 2 to 4 weeks.

Can GLP-1 agonists be combined with other weight-loss drugs? Yes, in some cases, under provider supervision. Common combinations include GLP-1 agonists with SGLT2 inhibitors for type 2 diabetes, or with naltrexone/bupropion for additional appetite control. Combination should not be initiated without provider review.

What's the difference between GLP-1 agonists and DPP-4 inhibitors? DPP-4 inhibitors (sitagliptin, linagliptin) block the enzyme that degrades native GLP-1, raising GLP-1 levels modestly. GLP-1 agonists are themselves the activator, producing far higher receptor activation. DPP-4 inhibitors are weight-neutral; GLP-1 agonists drive weight loss.

Sources

1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
3. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
4. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
5. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
6. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
7. Davies MJ, et al. Tirzepatide and gastric emptying. Diabetes Care. 2023.
8. Hanssen R, et al. Effect of semaglutide on food cue reactivity. Diabetes Obes Metab. 2023.
9. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121-130.
10. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight regain (STEP 4). JAMA. 2021;325(14):1414-1425.
11. FDA prescribing information, Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Byetta, Bydureon, Rybelsus, Adlyxin.
12. American Association of Clinical Endocrinology, Comprehensive type 2 diabetes management algorithm, 2023.
13. The Obesity Society and American Society for Metabolic and Bariatric Surgery joint guidelines, 2022.
14. National Institute of Diabetes and Digestive and Kidney Diseases, GLP-1 receptor agonists overview.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Trulicity, Byetta, Bydureon, Adlyxin, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.